Trial Profile

An Open-label, Single-ascending Dose Phase I Study to Evaluate the Safety and Tolerability of STSA-1002 Combined With STSA-1005 in Healthy Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STSA-1002 (Primary) ; STSA-1005 (Primary)
Indications Autoimmune disorders; COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions
Sponsors Staidson Beijing BioPharmaceuticals

Most Recent Events

20 May 2024 Status changed from recruiting to discontinued.
27 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Aug 2024.
27 Dec 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com